Clinical trial
CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in…
NCT01395745 · Anthera Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT01395745 |
|---|---|
| Title | CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With Systemic Lupus Erythematosus |
| Acronym | CHABLIS-SC1 |
| Lead sponsor | Anthera Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Systemic Lupus Erythematosus |
| Intervention type | Drug |
| Interventions | blisibimod, Placebo |
| Enrollment | 442 |
| Start date | Feb 1, 2013 |
| Primary completion | Jul 1, 2016 |
| Completion | Oct 1, 2016 |
| First posted | Jul 18, 2011 |
| Last update posted | Feb 3, 2017 |
| Countries | Belarus, Brazil, Colombia, Georgia, Guatemala, Hong Kong, India, Malaysia, Mexico, Philippines, Russia, Singapore and 4 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: